source
- Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer resultsLilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
- AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trialAstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…Endpoints · 3mo agoPositive readoutPositive